Robustelli della Cuna G, Pavesi L, Knerich R, Preti P, Paoletti P
J Neurooncol. 1984;2(3):237-40. doi: 10.1007/BF00253275.
Thirty-one patients with metastatic brain tumors were treated with Radiotherapy (RT) and CCNU or with RT, CCNU and Levamisole (LMS) in a randomized clinical trial. Twenty-seven were evaluable. All patients were submitted to whole brain radiation (50 +/- 5 Gy) and CCNU (130 mg/m2 p.o. every 8 weeks). 15 also received Levamisole (2.5 mg/kg p.o. daily for 3 weeks in the first month, for 2 weeks in the second, and then once a week monthly until progression). Primary tumor was predominantly lung cancer (22/27) and brain lesions were generally multiple (24/27). The overall response rate was 35% in the RT plus CCNU treated group and 38% in the RT plus CCNU plus LMS treated group. The median survival time was similar and not statistically different in both groups (7 versus 6 months). No important side effects were observed either in the RT + CCNU or in the RT + CCNU + LMS treated groups. The absence of combined depression of T-cell levels and responsiveness of lymphocytes to mitogens suggests that thymus dependent immunity could be improved by LMS administration. However, such improvement had no impact on duration of survival in patients with metastatic brain tumors.
在一项随机临床试验中，31例转移性脑肿瘤患者接受了放疗（RT）联合洛莫司汀（CCNU）治疗，或放疗、CCNU及左旋咪唑（LMS）联合治疗。27例患者可进行评估。所有患者均接受全脑放疗（50±5 Gy）及CCNU治疗（130 mg/m²口服，每8周一次）。15例患者还接受了左旋咪唑治疗（第1个月每日口服2.5 mg/kg，共3周；第2个月每日口服2.5 mg/kg，共2周；此后每月口服一次，每次2.5 mg/kg，直至病情进展）。原发肿瘤主要为肺癌（22/27），脑部病变通常为多发（24/27）。RT加CCNU治疗组的总缓解率为35%，RT加CCNU加LMS治疗组的总缓解率为38%。两组的中位生存时间相似，无统计学差异（7个月对6个月）。RT + CCNU治疗组和RT + CCNU + LMS治疗组均未观察到严重副作用。T细胞水平和淋巴细胞对丝裂原反应性未出现联合抑制，这表明给予LMS可改善胸腺依赖性免疫。然而，这种改善对转移性脑肿瘤患者的生存时间并无影响。
